Dawood Shaheenah, Ueno Naoto T, Cristofanilli Massimo
Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates.
Semin Oncol. 2008 Feb;35(1):64-71. doi: 10.1053/j.seminoncol.2007.11.012.
The multidisciplinary management of inflammatory breast cancer (IBC) includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and, in hormone receptor-positive disease, hormonal therapy. The use of induction chemotherapy with anthracyclines and taxanes somewhat improved the prognosis and local control of patients with IBC compared to local modalities alone. Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease.
炎性乳腺癌（IBC）的多学科管理包括新辅助全身化疗、手术、放疗，对于激素受体阳性疾病还包括激素治疗。与单纯局部治疗方式相比，使用蒽环类药物和紫杉烷类进行诱导化疗在一定程度上改善了IBC患者的预后和局部控制情况。对该疾病生物学特征的深入了解促使了靶向治疗（如曲妥珠单抗和拉帕替尼）的发展，这些靶向治疗正在改变这种侵袭性疾病的治疗结果。
